TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31659242

Group type: EXPERIMENTAL
Intervention: Cinnamon supplementation (3g daily)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo (3g daily)
Number of subjects: 44
Study: 27932411

Group type: EXPERIMENTAL
Intervention: MOD-4023 (once-weekly dosing at 18.5%, 37%, 55.5%, or 123.4% of individual cumulative weekly molar hGH dose)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: MOD-4023 (once-weekly dosing at 61.7% molar hGH content during Stage B)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: MOD-4023 (various dosing cohorts)
Number of subjects: 54
Study: 25754018

Group type: EXPERIMENTAL
Intervention: Novel X-ray imaging technology
Number of subjects: 70

Group type: COMPARATOR
Intervention: Reference X-ray system
Number of subjects: 70
Study: 23441963

Group type: EXPERIMENTAL
Intervention: 8 mg extract Sceletium tortuosum (Zembrin)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: 25 mg extract Sceletium tortuosum (Zembrin)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 21046132

Group type: EXPERIMENTAL
Intervention: Serum CA-125 concentrations in preeclamptic pregnancies (mild and severe)
Number of subjects: 242
Study: 19416039

Group type: EXPERIMENTAL
Intervention: Modafinil (100 mg/d during weeks 1-2, 200 mg during weeks 3-4)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Modafinil
Number of subjects: 0
Study: 17081839

Group type: EXPERIMENTAL
Intervention: Energy-content labels on non-energy-containing beverage selection panels
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Labels plus motivational posters
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 8
Study: 14691579

Group type: EXPERIMENTAL
Intervention: Stenting plus abciximab
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: Thrombolysis (alteplase alone or alteplase plus abciximab)
Number of subjects: 292

Group type: COMPARATOR
Intervention: Pl(A2) allele carriers
Number of subjects: 292

Group type: COMPARATOR
Intervention: Pl(A1/A1) patients
Number of subjects: 292
Study: 9621781

Group type: EXPERIMENTAL
Intervention: Specialized diet with adjusted energy intake, increased fish and antioxidants
Number of subjects: 109

Group type: COMPARATOR
Intervention: Control group (no specialized diet)
Number of subjects: 109
Study: 7800355

Group type: EXPERIMENTAL
Intervention: Treatment groups (specific treatments not detailed in the abstract)
Number of subjects: 438
Study: 3279747

Group type: EXPERIMENTAL
Intervention: Sucrose (120 g)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Starch (120 g)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Fat + Protein meal
Number of subjects: 10
Study: 31821992

Group type: EXPERIMENTAL
Intervention: Supervised progressive stabilization exercise (SE)
Number of subjects: 40

Group type: COMPARATOR
Intervention: General exercise (GE)
Number of subjects: 40
Study: 29170904

Group type: EXPERIMENTAL
Intervention: Endurance exercise training (ET group) for 5 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sedentary control (SC group)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Endurance exercise training (ET group)
Number of subjects: 20
Study: 28341069

Group type: EXPERIMENTAL
Intervention: Open surgery
Number of subjects: 165

Group type: COMPARATOR
Intervention: Ultrasound-guided corticosteroid injection
Number of subjects: 165
Study: 25746695

Group type: EXPERIMENTAL
Intervention: Ventilatory time (VT) during first admission
Number of subjects: 42
Study: 23340588

Group type: EXPERIMENTAL
Intervention: Pressure support
Number of subjects: 316

Group type: COMPARATOR
Intervention: Tracheostomy collar
Number of subjects: 316
Study: 20931221

Group type: EXPERIMENTAL
Intervention: MODs 6A-F
Number of subjects: 9

Group type: COMPARATOR
Intervention: MODs 1-6A
Number of subjects: 9

Group type: COMPARATOR
Intervention: MODs 1-6B
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: MODs 1-6A, 1-6B, and 6A-F
Number of subjects: 9
Study: 19942752

Group type: EXPERIMENTAL
Intervention: ZeroFly plastic sheeting treated with deltamethrin
Number of subjects: 3

Group type: COMPARATOR
Intervention: Untreated plastic sheet
Number of subjects: 3

Group type: COMPARATOR
Intervention: No sheet area
Number of subjects: 3
Study: 16389539

Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus GR‐1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri B‐54 and RC‐14
Number of subjects: 0

Group type: COMPARATOR
Intervention: Probiotics (general)
Number of subjects: 0
Study: 15573828

Group type: EXPERIMENTAL
Intervention: Education programme (stroke information manual and education meetings every two weeks)
Number of subjects: 170

Group type: COMPARATOR
Intervention: Usual practice (control group)
Number of subjects: 170
Study: 11391261

Group type: EXPERIMENTAL
Intervention: Amoxicillin‐clavulanate potassium (2-week course)
Number of subjects: 203

Group type: COMPARATOR
Intervention: Control group (no antibiotics)
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Comparison between groups
Number of subjects: 203
Study: 9404747

Group type: EXPERIMENTAL
Intervention: Combination of ipratropium bromide (IB) and albuterol sulfate (ALB)
Number of subjects: 652

Group type: COMPARATOR
Intervention: Albuterol sulfate (ALB)
Number of subjects: 652

Group type: COMPARATOR
Intervention: Ipratropium bromide (IB)
Number of subjects: 652
Study: 7952987

Group type: EXPERIMENTAL
Intervention: Nefazodone
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 283

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 283
Study: 3422105

Group type: EXPERIMENTAL
Intervention: Lovastatin (20 mg twice daily)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 30457948

Group type: EXPERIMENTAL
Intervention: Dental varnish containing casein phosphopeptide‐amorphous calcium phosphate and fluoride (CPP‐ACP, MI varnish, GC Europe)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Bioglass and fluoride (BGA, Experimental, Dentsply Sirona)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Fluoride alone (NUPRO, Dentsply Sirona)
Number of subjects: 12

Group type: COMPARATOR
Intervention: No treatment (Control group)
Number of subjects: 12
Study: 28517948

Group type: EXPERIMENTAL
Intervention: Coping With Voices (CWV) program
Number of subjects: 37

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 37
Study: 28053714

Group type: EXPERIMENTAL
Intervention: Active Respiratory Muscle Training (RMT)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Sham Respiratory Muscle Training (RMT)
Number of subjects: 3
Study: 24078975

Group type: EXPERIMENTAL
Intervention: Erythritol powder applied by air-polishing (EPAP)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Scaling and root planing (SRP)
Number of subjects: 40
Study: 16371080

Group type: EXPERIMENTAL
Intervention: i.v. atilmotin 6, 30, 60 microg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vehicle (placebo)
Number of subjects: 0
Study: 12810502

Group type: EXPERIMENTAL
Intervention: 10 mg of alefacept
Number of subjects: 507

Group type: EXPERIMENTAL
Intervention: 15 mg of alefacept
Number of subjects: 507

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 507
Study: 10021470

Group type: EXPERIMENTAL
Intervention: Growth hormone treatment (0.3 mg per kilogram of body weight per week) for 2 to 10 years
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Growth hormone treatment
Number of subjects: 121
Study: 8672321

Group type: EXPERIMENTAL
Intervention: IL-10 during CPB
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Pro-inflammatory cytokines (IL-1, IL-8, TNF)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: IL-1 receptor antagonist (IL-1ra) and TNF soluble receptors (TNFsr)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Granulocyte adhesion molecule expression
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Fentanyl 175 micrograms with heparin 1050 u
Number of subjects: 20

Group type: COMPARATOR
Intervention: Heparin alone 1050 u
Number of subjects: 20
Study: 1981223

Group type: COMPARATOR
Intervention: Control group (vasodilators with no known inhibitory effect on platelet function)
Number of subjects: 590

Group type: COMPARATOR
Intervention: Dipyridamole (DP) 50 mg 3 times a day
Number of subjects: 590

Group type: EXPERIMENTAL
Intervention: ASA 300 mg once a day
Number of subjects: 590

Group type: EXPERIMENTAL
Intervention: ASA 300 mg once in combination with DP 50 mg 3 times a day
Number of subjects: 590

Group type: EXPERIMENTAL
Intervention: ASA 100 mg once a day
Number of subjects: 590

Group type: COMPARATOR
Intervention: Non-ASA group (combined control and DP groups)
Number of subjects: 590

Group type: EXPERIMENTAL
Intervention: ASA3 group (combined ASA 300 mg and ASADP groups)
Number of subjects: 590
Study: 7283711

Group type: EXPERIMENTAL
Intervention: Doxycycline
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 29328522

Group type: EXPERIMENTAL
Intervention: Cassava flour slurry (CFS)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Commercial gel
Number of subjects: 30
Study: 27787547

Group type: EXPERIMENTAL
Intervention: Girentuximab (50 mg loading dose followed by 20 mg weekly for 24 weeks)
Number of subjects: 864

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 864

Group type: EXPERIMENTAL
Intervention: Girentuximab
Number of subjects: 864
Study: 25556383

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (1200 mg/day)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 24005138

Group type: EXPERIMENTAL
Intervention: 4% liposomal lidocaine
Number of subjects: 10

Group type: COMPARATOR
Intervention: 2.5% lidocaine and 2.5% prilocaine
Number of subjects: 10
Study: 21439642

Group type: EXPERIMENTAL
Intervention: povidone iodine 2.5% solution
Number of subjects: 394

Group type: COMPARATOR
Intervention: tetracycline 1% ointment
Number of subjects: 394
Study: 18201138

Group type: EXPERIMENTAL
Intervention: Brimonidine tartrate 0.2% twice-daily
Number of subjects: 26

Group type: COMPARATOR
Intervention: Artificial tears (control)
Number of subjects: 26
Study: 15842288

Group type: EXPERIMENTAL
Intervention: Tocolysis for repeat external cephalic version (ECV)
Number of subjects: 124
Study: 12898792

Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate (Andriol) 160 mg/day for 3 months
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate (Andriol)
Number of subjects: 39
Study: 10534261

Group type: EXPERIMENTAL
Intervention: Vigabatrin (VGB) at a target dose of 50 mg/kg
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo (PLC)
Number of subjects: 14
Study: 8707781

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 50, 100, or 250 micrograms
Number of subjects: 331
Study: 1746428

Group type: EXPERIMENTAL
Intervention: Enalapril (2.5 mg orally at baseline and again 12 hours later)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study: 7185276

Group type: EXPERIMENTAL
Intervention: Rehearsal group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Modeling group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Discussion control group
Number of subjects: 0
Study: 31772615

Group type: EXPERIMENTAL
Intervention: Fimasartan
Number of subjects: 80

Group type: COMPARATOR
Intervention: Valsartan
Number of subjects: 80
Study: 27604240

Group type: EXPERIMENTAL
Intervention: PEP + omega-3
Number of subjects: 72
Study: 26151891

Group type: EXPERIMENTAL
Intervention: Microscopic retroperitoneal varicocelectomy (MRV)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Microscopic subinguinal varicocelectomy (MSV)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both MRV and MSV
Number of subjects: 80
Study: 25118794

Group type: EXPERIMENTAL
Intervention: Positively Smoke Free on the Web (PSFW)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Standard care (brief advice to quit and self-help brochure)
Number of subjects: 138
Study: 22261824

Group type: EXPERIMENTAL
Intervention: Low amount-high intensity
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: High amount-high intensity
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Low amount-moderate intensity
Number of subjects: 163
Study: 20020589

Group type: EXPERIMENTAL
Intervention: Compomer restoration
Number of subjects: 20

Group type: COMPARATOR
Intervention: Amalgam restoration
Number of subjects: 20
Study: 17335327

Group type: EXPERIMENTAL
Intervention: Day hospital care
Number of subjects: 1117

Group type: COMPARATOR
Intervention: Conventional inpatient care
Number of subjects: 1117
Study: 15220229

Group type: EXPERIMENTAL
Intervention: Antimicrobial therapy for UTI
Number of subjects: 765

Group type: COMPARATOR
Intervention: Control group (type 2 diabetic patients without UTI)
Number of subjects: 765
Study: 11821986

Group type: EXPERIMENTAL
Intervention: 1% aqueous solution of poloxamine 1107 (treated)
Number of subjects: 6

Group type: COMPARATOR
Intervention: 0.9% saline (control)
Number of subjects: 6
Study: 9822096

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Nifedipine GITS
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 8558397

Group type: EXPERIMENTAL
Intervention: Antiseptic mouthrinse
Number of subjects: 20

Group type: COMPARATOR
Intervention: 5% hydroalcohol placebo mouthrinse
Number of subjects: 20
Study: 2758540

Group type: EXPERIMENTAL
Intervention: Neostigmine 0.04 mg.kg‐1 with varying doses of atropine (0.014 to 0.04 mg.kg‐1) in Group A
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Neostigmine 0.06 mg.kg‐1 with varying doses of atropine (0.02 to 0.04 mg.kg‐1) in Group B
Number of subjects: 70
Study: 900826

Group type: EXPERIMENTAL
Intervention: 5000 units of subcutaneous heparin 2 hr before the operation, then 5000 units 3 times daily for 6 days
Number of subjects: 99

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: 5000 units of subcutaneous heparin
Number of subjects: 99
Study: 31557874

Group type: EXPERIMENTAL
Intervention: Standing desks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional desks
Number of subjects: 0
Study: 27072928

Group type: EXPERIMENTAL
Intervention: Physical activity and fitness programme (3 times a week for 8 months)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Care as usual (control group)
Number of subjects: 151
Study: 26230296

Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 26866095

Group type: EXPERIMENTAL
Intervention: Boric acid (powder every night for a week)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Fluconazole
Number of subjects: 150
Study: 21639658

Group type: EXPERIMENTAL
Intervention: Brief alliance-training workshop
Number of subjects: 57

Group type: COMPARATOR
Intervention: Delayed-training control condition
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Both conditions
Number of subjects: 57
Study: 19622685

Group type: EXPERIMENTAL
Intervention: 900 mg nefiracetam per day
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: 600 mg nefiracetam per day
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 16536342

Group type: EXPERIMENTAL
Intervention: Self-etching adhesives (AdheSE, Adper Prompt L-Pop, Clearfil SE Bond, iBond, OptiBond Solo Plus - Self-Etch Adhesive System, Xeno III)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Etch-and-rinse adhesive system (OptiBond FL)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Negative control (Gluma Classic with 0.5 M EDTA)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Positive control (OptiBond FL)
Number of subjects: 48
Study: 14641263

Group type: EXPERIMENTAL
Intervention: Levofloxacin 0.5% eye drops, one drop every 15 min for four doses prior to surgery
Number of subjects: 59

Group type: COMPARATOR
Intervention: Ciprofloxacin 0.3% eye drops, one drop every 15 min for four doses prior to surgery
Number of subjects: 59
Study: 11677363

Group type: EXPERIMENTAL
Intervention: 24 h SBP or PP standard deviation
Number of subjects: 1663

Group type: EXPERIMENTAL
Intervention: 24 h average SBP or PP
Number of subjects: 1663

Group type: EXPERIMENTAL
Intervention: Day-night or clinic-day SBP and PP differences
Number of subjects: 1663
Study: 9373657

Group type: EXPERIMENTAL
Intervention: Intramuscular artemether
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Artemisinin suppositories
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Artesunate (intramuscular)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Intravenous artesunate
Number of subjects: 175
Study: 1554153

Group type: EXPERIMENTAL
Intervention: Deproteinized hemodialysate 20% for infusion, 20 intra-arterial infusions over 4 weeks
Number of subjects: 58

Group type: COMPARATOR
Intervention: Bencyclan 250 mg in 250 mL saline 0.9%, 20 intra-arterial infusions over 4 weeks
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Deproteinized hemodialysate 20% for infusion
Number of subjects: 58
Study: 3993535

Group type: EXPERIMENTAL
Intervention: Acebutolol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quinidine
Number of subjects: 0
Study: 30773148

Group type: EXPERIMENTAL
Intervention: Affect-focused treatments (Interpersonal Psychotherapy for PTSD; Panic-Focused Psychodynamic Psychotherapy for PD)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Exposure-based treatments (Prolonged Exposure for PTSD; Cognitive Behavioral Therapy or Applied Relaxation Training for PD)
Number of subjects: 59
Study: 29704456

Group type: EXPERIMENTAL
Intervention: 0.05% tretinoin cream applied three nights a week
Number of subjects: 24

Group type: COMPARATOR
Intervention: 5% tretinoin peel applied every 2 weeks
Number of subjects: 24
Study: 27930530

Group type: EXPERIMENTAL
Intervention: Remifentanil (infused at 0.1 μg/kg/min and demand boluses of 0.1 μg/kg)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 152
Study: 24484541

Group type: EXPERIMENTAL
Intervention: Intensive physiotherapy involving both hospital and home-based functional exercise rehabilitation
Number of subjects: 440

Group type: COMPARATOR
Intervention: Standard of care consisting of home exercises
Number of subjects: 440
Study: 21732113

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) at 830 nm, 86 mW, 92.1 J/cm², 0.25 J, 3 s/point, at 20 points, repeated every 48 hours for 14 days
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (simulated irradiation)
Number of subjects: 8
Study: 20232173

Group type: COMPARATOR
Intervention: T-tube
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Primary closure
Number of subjects: 122
Study: 19099235

Group type: EXPERIMENTAL
Intervention: Dual release tablet (DRT-1) 300 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional immediate release tablet (Daxfen, 300 mg)
Number of subjects: 0
Study: 15796633

Group type: EXPERIMENTAL
Intervention: Increased therapist directiveness (interpretation, confrontation, introduction of topics)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Low therapist directiveness
Number of subjects: 141
Study: 11961148

Group type: EXPERIMENTAL
Intervention: Erythromycin-resistant group A streptococci isolates
Number of subjects: 100

Group type: COMPARATOR
Intervention: Community isolates of group A streptococci
Number of subjects: 100
Study: 10646165

Group type: EXPERIMENTAL
Intervention: Alcohol condition (BAC 0.10%)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Sustained wakefulness condition (28 hours awake)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo condition (non-alcoholic beverage)
Number of subjects: 22
Study: 8698253

Group type: EXPERIMENTAL
Intervention: Infected premature infants
Number of subjects: 49
Study: 2132274

Group type: EXPERIMENTAL
Intervention: Chewable tablets containing pyridoxine and heat killed lactic bacteria
Number of subjects: 245

Group type: COMPARATOR
Intervention: Placebo tablets with pyridoxine only
Number of subjects: 245
Study: 513885

Group type: EXPERIMENTAL
Intervention: Self-administered health history questionnaire (SAHHQ)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 77
Study: 6278914

Group type: EXPERIMENTAL
Intervention: Prolonged small dose propranolol (30 mg daily for 2 weeks)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Serial dose reduction of propranolol (for 6 to 9 days)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo therapy (for 2 additional weeks after dose reduction)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Prolonged small dose propranolol (30 mg daily)
Number of subjects: 9
Study: 31359178

Group type: EXPERIMENTAL
Intervention: 3 g IA‐TXA
Number of subjects: 80

Group type: COMPARATOR
Intervention: 500 mg IA‐TXA
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 80
Study: 27893569

Group type: EXPERIMENTAL
Intervention: Assessment of Compensatory Sit-to-Stand Maneuvers in People With Dementia (ACSID)
Number of subjects: 97
Study: 28026727

Group type: EXPERIMENTAL
Intervention: Dynamic IDSD implantation
Number of subjects: 12

Group type: COMPARATOR
Intervention: Decompression alone
Number of subjects: 12
Study: 24678939

Group type: EXPERIMENTAL
Intervention: Renal denervation
Number of subjects: 535

Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 535
Study: 23272227

Group type: EXPERIMENTAL
Intervention: artesunate monotherapy (2 mg/kg/day)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: artesunate monotherapy (4 mg/kg/day)
Number of subjects: 126

Group type: COMPARATOR
Intervention: quinine plus doxycycline TID for 7 days
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: artesunate monotherapy (2 mg/kg/day) and (4 mg/kg/day)
Number of subjects: 126
Study: 19147138

Group type: EXPERIMENTAL
Intervention: Women with previous GDM
Number of subjects: 164

Group type: COMPARATOR
Intervention: Control group (lean women with negative screening for GDM)
Number of subjects: 164
Study: 17071945

Group type: EXPERIMENTAL
Intervention: Bangkok schoolchildren
Number of subjects: 184
Study: 15931222

Group type: EXPERIMENTAL
Intervention: Intranasal administration of oxytocin
Number of subjects: 0
Study: 12149762

Group type: EXPERIMENTAL
Intervention: Tacrolimus (T) with azathioprine and prednisolone
Number of subjects: 40

Group type: COMPARATOR
Intervention: Cyclosporin (C) with azathioprine and prednisolone
Number of subjects: 40